Published in J Virol on November 01, 2005
Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog (2009) 4.88
Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol (2009) 1.45
Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol (2007) 1.41
Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J Virol (2008) 1.39
T cell-dependence of Lassa fever pathogenesis. PLoS Pathog (2010) 1.25
Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J Virol (2009) 1.19
A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine (2007) 1.13
Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine (2008) 1.09
Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol (2006) 1.07
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology (2006) 1.06
Unpaired 5' ppp-nucleotides, as found in arenavirus double-stranded RNA panhandles, are not recognized by RIG-I. J Biol Chem (2010) 1.03
Arenavirus variations due to host-specific adaptation. Viruses (2013) 0.99
Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res (2011) 0.94
A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. J Infect Dis (2013) 0.94
Development of live-attenuated arenavirus vaccines based on codon deoptimization. J Virol (2015) 0.91
Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog (2006) 0.91
Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine (2010) 0.90
Advanced vaccine candidates for Lassa fever. Viruses (2012) 0.90
Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes (2006) 0.88
Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. Antiviral Res (2011) 0.88
Rescue of a recombinant Machupo virus from cloned cDNAs and in vivo characterization in interferon (αβ/γ) receptor double knockout mice. J Virol (2013) 0.88
Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. PLoS Pathog (2013) 0.87
An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J (2013) 0.86
Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate. PLoS Negl Trop Dis (2013) 0.85
Reverse genetics approaches to combat pathogenic arenaviruses. Antiviral Res (2008) 0.85
Genomic and biological characterization of aggressive and docile strains of lymphocytic choriomeningitis virus rescued from a plasmid-based reverse-genetics system. J Gen Virol (2008) 0.85
The search for animal models for Lassa fever vaccine development. Expert Rev Vaccines (2013) 0.84
Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines. J Virol (2015) 0.82
A substitution in the transmembrane region of the glycoprotein leads to an unstable attenuation of Machupo virus. J Virol (2014) 0.82
Comparative pathogenesis and systems biology for biodefense virus vaccine development. J Biomed Biotechnol (2010) 0.82
A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis (2015) 0.80
Shedding dynamics of Morogoro virus, an African arenavirus closely related to Lassa virus, in its natural reservoir host Mastomys natalensis. Sci Rep (2015) 0.80
Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers. J Vaccines Vaccin (2012) 0.79
Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine (2012) 0.79
Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling. Bioeng Bugs (2011) 0.78
Immunobiology of Ebola and Lassa virus infections. Nat Rev Immunol (2017) 0.77
Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness. J Virol (2014) 0.77
Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate. J Virol (2013) 0.76
Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein. Virology (2016) 0.75
Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man. Future Virol (2015) 0.75
Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines. Expert Rev Vaccines (2016) 0.75
Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol (1998) 8.44
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
The completed sequence of lymphocytic choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein. Virology (1989) 3.29
Lassa fever. Curr Top Microbiol Immunol (2002) 3.01
Genetic diversity among Lassa virus strains. J Virol (2000) 3.00
Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus. J Virol (1988) 2.82
Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol (1994) 2.65
Genetic reassortment of Rift Valley fever virus in nature. J Virol (1999) 2.43
Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis (1980) 2.38
Ngari virus is a Bunyamwera virus reassortant that can be associated with large outbreaks of hemorrhagic fever in Africa. J Virol (2004) 1.93
Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol (1987) 1.83
Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine (1990) 1.82
Influenza vaccines: present and future. J Clin Invest (2002) 1.74
Effective vaccine for lassa fever. J Virol (2000) 1.74
Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology (1986) 1.69
Naturally occurring Sin Nombre virus genetic reassortants. Virology (1995) 1.67
Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol (2001) 1.66
Complete nucleotide sequences of the M and S segments of two hantavirus isolates from California: evidence for reassortment in nature among viruses related to hantavirus pulmonary syndrome. Virology (1995) 1.64
Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. J Virol (1985) 1.60
Characterization of the interaction of lassa fever virus with its cellular receptor alpha-dystroglycan. J Virol (2005) 1.56
Sequence analysis of L RNA of Lassa virus. Virology (2004) 1.50
Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun (1982) 1.47
Completion of the Lassa fever virus sequence and identification of a RING finger open reading frame at the L RNA 5' End. Virology (1997) 1.44
Genetic reassortment among viruses causing hantavirus pulmonary syndrome. Virology (1998) 1.42
Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products. Virus Res (1991) 1.37
Generation of reassortants between African arenaviruses. Virology (1992) 1.33
Pathogenicity of Hantaan virus in newborn mice: genetic reassortant study demonstrating that a single amino acid change in glycoprotein G1 is related to virulence. J Virol (2000) 1.29
The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250 kDa protein with monospecific antiserum. J Gen Virol (1997) 1.29
Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol (2000) 1.24
Evidence of segment reassortment in Crimean-Congo haemorrhagic fever virus. J Gen Virol (2004) 1.17
Towards a human Lassa fever vaccine. Rev Med Virol (2001) 1.12
Genetic reassortants of lymphocytic choriomeningitis virus: unexpected disease and mechanism of pathogenesis. J Virol (1986) 1.10
Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology (2004) 1.09
Lassa fever vaccine. Expert Rev Vaccines (2004) 1.08
Adaptation of Puumala hantavirus to cell culture is associated with point mutations in the coding region of the L segment and in the noncoding regions of the S segment. J Virol (2003) 1.04
Neuroattenuation of an avirulent bunyavirus variant maps to the L RNA segment. J Virol (1991) 1.03
Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology (2005) 1.03
Reassortant analysis of guinea pig virulence of pichinde virus variants. Virology (2001) 1.02
Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J Med Virol (2002) 1.01
Sequence comparison of the large genomic RNA segments of two strains of lymphocytic choriomeningitis virus differing in pathogenic potential for guinea pigs. Virus Genes (1998) 0.96
Exquisite specificity of adoptive immunization in arenavirus-infected mice. Antiviral Res (1985) 0.94
LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration. Arch Virol (2004) 0.94
Ribonucleic acids of Machupo and Lassa viruses. Arch Virol (1984) 0.93
Reassortment of La Crosse and Tahyna bunyaviruses in Aedes triseriatus mosquitoes. Virus Res (1991) 0.92
Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. J Hum Virol (2001) 0.91
[The isolation and characteristics of reassortants between the Lassa and Mopeia arenaviruses]. Vopr Virusol (1991) 0.86
Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Drugs R D (2003) 0.86
Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann (2004) 0.83
Sedimentation analysis of the RNAs isolated from interfering particles of Lassa and Machupo viruses. Acta Virol (1985) 0.78
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol (2002) 2.77
Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci (2003) 2.67
Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci (2009) 2.08
Housing density does not influence the longevity effect of calorie restriction. J Gerontol A Biol Sci Med Sci (2005) 1.85
Spontaneous heart disease in the adult chimpanzee (Pan troglodytes). J Med Primatol (2008) 1.72
Framework for leadership and training of Biosafety Level 4 laboratory workers. Emerg Infect Dis (2008) 1.66
Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol (2003) 1.56
Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. Clin Vaccine Immunol (2006) 1.50
Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A (2009) 1.45
Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol (2007) 1.41
Does reduced IGF-1R signaling in Igf1r+/- mice alter aging? PLoS One (2011) 1.39
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One (2013) 1.38
Spontaneous neoplasia in the baboon (Papio spp.). J Med Primatol (2007) 1.34
Effects of promyelocytic leukemia protein on virus-host balance. J Virol (2002) 1.28
Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun (2005) 1.28
Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol (2003) 1.25
Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med (2012) 1.24
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Early blood profiles of virus infection in a monkey model for Lassa fever. J Virol (2007) 1.20
Non-human primate fetal kidney transcriptome analysis indicates mammalian target of rapamycin (mTOR) is a central nutrient-responsive pathway. J Physiol (2006) 1.15
HIV-1 transgenic rats develop T cell abnormalities. Virology (2004) 1.14
A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine (2007) 1.13
A review of spontaneous neoplasia in baboons (Papio spp.). J Med Primatol (2005) 1.13
Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol (2013) 1.11
Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers. Emerg Infect Dis (2009) 1.11
Effects of maternal global nutrient restriction on fetal baboon hepatic insulin-like growth factor system genes and gene products. Endocrinology (2009) 1.11
Common marmosets (Callithrix jacchus) as a nonhuman primate model to assess the virulence of eastern equine encephalitis virus strains. J Virol (2008) 1.10
Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine (2008) 1.09
The impact of regulations, safety considerations and physical limitations on research progress at maximum biocontainment. Viruses (2012) 1.08
A novel Brucella isolate in association with two cases of stillbirth in non-human primates - first report. J Med Primatol (2009) 1.07
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology (2006) 1.06
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother (2005) 1.05
A small nonhuman primate model for filovirus-induced disease. Virology (2011) 1.03
Rapid assembly of sensitive antigen-capture assays for Marburg virus, using in vitro selection of llama single-domain antibodies, at biosafety level 4. J Infect Dis (2007) 1.02
Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology (2009) 1.02
Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J Med Virol (2002) 1.01
Toxicity, antimicrobial and anthelmintic activities of Vernonia guineensis Benth. (Asteraceae) crude extracts. J Ethnopharmacol (2012) 1.00
Past, present, and future of arenavirus taxonomy. Arch Virol (2015) 1.00
Short report: quantification of leishmaniavirus RNA in clinical samples and its possible role in pathogenesis. Am J Trop Med Hyg (2003) 1.00
Arenavirus variations due to host-specific adaptation. Viruses (2013) 0.99
Thioredoxin 1 overexpression extends mainly the earlier part of life span in mice. J Gerontol A Biol Sci Med Sci (2011) 0.99
The prolonged effect of repeated maternal glucocorticoid exposure on the maternal and fetal leptin/insulin-like growth factor axis in Papio species. Reprod Sci (2008) 0.99
Spontaneous pathology of the common marmoset (Callithrix jacchus) and tamarins (Saguinus oedipus, Saguinus mystax). J Med Primatol (2009) 0.98
Mortality in captive baboons with seizures: a new model for SUDEP? Epilepsia (2009) 0.98
Natural Chagas disease in four baboons. J Med Primatol (2008) 0.97
Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol (2009) 0.97
HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand. Intervirology (2007) 0.97
The frequency of lymphocytic and reflux esophagitis in non-human primates. Int J Clin Exp Pathol (2008) 0.97
Vaccinia virus inhibits T cell receptor-dependent responses by human gammadelta T cells. J Infect Dis (2006) 0.97
Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II. PLoS Pathog (2013) 0.97
Gene expression in primate liver during viral hemorrhagic fever. Virol J (2009) 0.97
Combination therapy reduces self-injurious behavior in a chimpanzee (Pan Troglodytes Troglodytes): a case report. J Appl Anim Welf Sci (2007) 0.96
Natural pathology of the Baboon (Papio spp.). J Med Primatol (2011) 0.96
Trypanosoma cruzi in non-human primates with a history of stillbirths: a retrospective study (Papio hamadryas spp.) and case report (Macaca fascicularis). J Med Primatol (2008) 0.95
Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques. J Virol (2015) 0.94
The columnar-lined mucosa in the distal esophagus. A preliminary study in baboons. In Vivo (2009) 0.94
The baboon model (Papio hamadryas) of fetal loss: maternal weight, age, reproductive history and pregnancy outcome. J Med Primatol (2008) 0.94
Endothelial senescence after high-cholesterol, high-fat diet challenge in baboons. Am J Physiol Heart Circ Physiol (2007) 0.93
Increased virus replication and virulence after serial passage of human immunodeficiency virus type 2 in baboons. J Virol (2003) 0.93
A case report of hepatocellular carcinoma and focal nodular hyperplasia with a myelolipoma in two chimpanzees and a review of spontaneous hepatobiliary tumors in non-human primates. J Med Primatol (2004) 0.93
Reductions in serum IGF-1 during aging impair health span. Aging Cell (2013) 0.93
Differential effects of enalapril and losartan on body composition and indices of muscle quality in aged male Fischer 344 × Brown Norway rats. Age (Dordr) (2010) 0.92
The proline-rich homeodomain (PRH/HEX) protein is down-regulated in liver during infection with lymphocytic choriomeningitis virus. J Virol (2005) 0.92
Do long-lived mutant and calorie-restricted mice share common anti-aging mechanisms?--a pathological point of view. Age (Dordr) (2006) 0.92
Pathology of spontaneous air sacculitis in 37 baboons and seven chimpanzees and a brief review of the literature. J Med Primatol (2012) 0.91
Spontaneous ovarian tumors in twelve baboons: a review of ovarian neoplasms in non-human primates. J Med Primatol (2003) 0.91
International NeuroAIDS: prospects of HIV-1 associated neurological complications. Cell Res (2005) 0.91
Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine (2010) 0.90